BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Neothermia Corporation Announces Settlement Of Patent Litigation


10/19/2005 5:12:35 PM

NATICK, Mass., Jan. 27 /PRNewswire/ -- Neothermia Corporation today announced that it has reached an agreement with Rubicor Medical Corporation for the dismissal of patent infringement and breach of contract litigation filed against Rubicor by Neothermia. Under the terms of the agreement, both companies have agreed to dismiss their claims and counter claims relating to the litigation. The agreement is limited to U.S. Patent No. 6,514,248 B1 (the '248 patent') and its related patents, which remain valid, and has no affect on the remainder of Neothermia's patent portfolio.

Thomas M. Tully, Chief Executive Officer of Neothermia, commented, "This limited agreement allows us to focus our resources on marketing and sales efforts to further accelerate the growth of our business for the advanced en-bloc(R) Breast Biopsy System. Growing clinical evidence continues to demonstrate that the en-bloc(R) procedure can result in a significantly more accurate diagnosis than percutaneous core biopsy. Our extensive, powerful patent portfolio remains intact and enforceable."

About Neothermia Corporation

Founded in 1998, and based in Natick, Massachusetts, Neothermia is a privately held company focused on the design, development and marketing of innovative, minimally invasive systems for the volumetric excision of tissue for diagnostic and therapeutic applications in select cancer markets. The Company's lead product, the en-bloc(R) biopsy system, received approval from the Food and Drug Administration in June 2001. Initial products are targeted at breast biopsy and tumor excision.

For more information about Neothermia, please visit the Company's website at http://www.neothermia.com/.

Contact: Neothermia Corporation Rx Communications Group Thomas M. Tully, President & CEO Paula Schwartz (investors) 508-655-7820 917-322-2216 Tony H. Loke (media) 917-322-2164

Neothermia Corporation

CONTACT: Thomas M. Tully, President & CEO of Neothermia,+1-508-655-7820, or Investors, Paula Schwartz, +1-917-322-2216, or Media, TonyH. Loke, +1-917-322-2164, both of Rx Communications Group



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES